Figure 3From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 monthsIndividual pattern of antibody responses to MSP3 by vaccination dose with respect to vaccine type. Squares show children vaccinated with 15 μg MSP3, triangles show children vaccinated with 30 μg MSP3 and circles show children vaccinated with Engerix B. Lines connect median values. Abscissas: days post vaccination and ordinates: Elisa titers.Back to article page